GeoVax Labs (GOVX) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
VivoSim Labs is the larger company by market cap ($2.9 million vs $2.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOVX | VIVS |
|---|---|---|
| Share price | $0.2866 | $0.1772 |
| Market cap | $2.90M | $2.94M |
| 1-day change | -0.97% | -7.47% |
| EPS (TTM) | $-8.84 | $-4.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.75 | $3.41 |
| 52-week low | $0.277 | $0.17 |
| Distance from 52-week high | -98.18% | -94.80% |
| Analyst consensus | none | — |
| Avg. price target upside | +3389.18% | — |
| Average volume | 771.47K | 5.85M |
| Shares outstanding | 10.10M | 16.59M |
| Employees | 19 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GeoVax Labs
GOVX stock →GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
GOVX vs VIVS FAQ
Which is bigger, GeoVax Labs or VivoSim Labs?
VivoSim Labs (VIVS) is larger, with a market capitalization of $2.94M compared with $2.90M for GeoVax Labs (GOVX).
Are GeoVax Labs and VivoSim Labs in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for GeoVax Labs and Biotechnology: Biological Products (No Diagnostic Substances) for VivoSim Labs.